
Jonine D Figueroa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4837608/publications.pdf Version: 2024-02-01



IONINE D FICHEROA

#	Article	IF	CITATIONS
1	Relation of circulating estrogens with hair relaxer and skin lightener use among postmenopausal women in Ghana. Journal of Exposure Science and Environmental Epidemiology, 2023, 33, 301-310.	3.9	3
2	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
4	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
5	Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study. Breast Cancer Research, 2022, 24, 9.	5.0	4
6	OUP accepted manuscript. Neuro-Oncology, 2022, , .	1.2	0
7	Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women. Journal of the National Cancer Institute, 2022, 114, 1420-1424.	6.3	4
8	A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	1.7	6
9	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
10	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	2.9	11
11	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case–Control Studies. Environmental Health Perspectives, 2022, 130, 57006.	6.0	5
12	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
13	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	6.3	14
14	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
15	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
16	Relation of Quantitative Histologic and Radiologic Breast Tissue Composition Metrics With Invasive Breast Cancer Risk. JNCI Cancer Spectrum, 2021, 5, pkab015.	2.9	7
17	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
18	Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study. International Journal of Cancer, 2021, 148, 2712-2723.	5.1	33

#	Article	IF	CITATIONS
19	Risk factors for breast cancer development by tumor characteristics among women with benign breast disease. Breast Cancer Research, 2021, 23, 34.	5.0	14
20	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. Journal of the National Cancer Institute, 2021, 113, 1168-1176.	6.3	41
21	Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1397-1407.	2.5	7
22	Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya. Breast Cancer Research, 2021, 23, 68.	5.0	11
23	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications, 2021, 12, 4198.	12.8	24
24	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
25	Risk of missing colorectal cancer with a COVID-adapted diagnostic pathway using quantitative faecal immunochemical testing. BJS Open, 2021, 5, .	1.7	4
26	Discovery of structural deletions in breast cancer predisposition genes using whole genome sequencing data from > 2000 women of African-ancestry. Human Genetics, 2021, 140, 1449-1457.	3.8	4
27	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. Npj Precision Oncology, 2021, 5, 83.	5.4	4
28	Raised cardiovascular disease mortality after central nervous system tumor diagnosis: analysis of 171,926 patients from UK and USA. Neuro-Oncology Advances, 2021, 3, vdab136.	0.7	8
29	The impact of the Covid-19 pandemic on breast cancer early detection and screening. Preventive Medicine, 2021, 151, 106585.	3.4	68
30	Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States. Neuro-Oncology, 2021, 23, 979-989.	1.2	10
31	The impact of measures to curb COVID-19 on patient attendance at 10 hospitals in Machakos County, Kenya. Journal of Global Health, 2021, 11, 05016.	2.7	5
32	Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open, 2021, 6, 100331.	4.5	1
33	Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. Heart, 2020, 106, 1890-1897.	2.9	90
34	Longer-term (≥ 2Âyears) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 11622.	3.3	155
35	Breast cancer gene expression datasets do not reflect the disease at the population level. Npj Breast Cancer, 2020, 6, 39.	5.2	5
36	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. Npj Breast Cancer, 2020, 6, 41.	5.2	5

#	Article	IF	CITATIONS
37	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
38	Distinguishing between direct and indirect consequences of covid-19. BMJ, The, 2020, 369, m2377.	6.0	12
39	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
40	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. British Journal of Cancer, 2020, 123, 852-859.	6.4	30
41	Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A populationâ€based case–control study. International Journal of Cancer, 2020, 147, 1535-1547.	5.1	28
42	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
43	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
44	Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches. BMC Bioinformatics, 2020, 21, 30.	2.6	32
45	Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry. , 2020, , .		1
46	Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry. , 2020, , .		1
47	Abstract 4636: Breast cancer age-specific incidence rates among Ghanaian women by breast cancer risk factors: A study using census and population-based case-control study data. , 2020, , .		Ο
48	Abstract 4638: Associations of fecal microbial profiles with non-malignant breast disease and breast cancer in the Ghana Breast Health Study. , 2020, , .		0
49	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
50	Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients. Journal of Clinical Medicine, 2019, 8, 1868.	2.4	9
51	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
52	Recruiting population controls for case-control studies in sub-Saharan Africa: The Ghana Breast Health Study. PLoS ONE, 2019, 14, e0215347.	2.5	14
53	Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Modern Pathology, 2019, 32, 1244-1256.	5.5	51
54	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52

#	Article	IF	CITATIONS
55	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
56	The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients. International Journal of Cancer, 2019, 145, 70-77.	5.1	9
57	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
58	Reply to â€~Mosaic loss of chromosome Y in leukocytes matters'. Nature Genetics, 2019, 51, 7-9.	21.4	7
59	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
60	Abstract 622: Reproductive factors and breast cancer risk to women in Ghana, West Africa. , 2019, , .		0
61	Abstract LB-178: Performance of breast cancer polygenic risk score (PRS) in a Ghanaian population. , 2019, , .		1
62	The <i>BRCA2</i> c.68-7TÂ>ÂA variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
63	Serum insulinâ€like growth factor (IGF)â€l and IGF binding proteinâ€3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. International Journal of Cancer, 2018, 143, 496-507.	5.1	8
64	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. International Journal of Cancer, 2018, 143, 746-757.	5.1	19
65	Skin lighteners and hair relaxers as risk factors for breast cancer: results from the Ghana breast health study. Carcinogenesis, 2018, 39, 571-579.	2.8	24
66	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. International Journal of Epidemiology, 2018, 47, 526-536.	1.9	88
67	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Scientific Reports, 2018, 8, 6574.	3.3	51
68	The Relation of Type 2 Diabetes and Breast Cancer Incidence in Asian, Hispanic and African American Populations—A Review. Canadian Journal of Diabetes, 2018, 42, 100-105.	0.8	9
69	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology, 2018, 74, 784-795.	1.9	530
70	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
71	Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Research, 2017, 19, 8.	5.0	58
72	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75

#	Article	IF	CITATIONS
73	Design considerations for identifying breast cancer risk factors in a populationâ€based study in Africa. International Journal of Cancer, 2017, 140, 2667-2677.	5.1	30
74	Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa. Breast Cancer Research and Treatment, 2017, 162, 105-114.	2.5	49
75	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
76	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
77	Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis, 2017, 38, 1167-1179.	2.8	18
78	Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. International Journal of Cancer, 2017, 141, 1830-1840.	5.1	20
79	Age-related terminal duct lobular unit involution in benign tissues from Chinese breast cancer patients with luminal and triple-negative tumors. Breast Cancer Research, 2017, 19, 61.	5.0	16
80	Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. International Journal of Cancer, 2017, 140, 825-832.	5.1	9
81	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67
82	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
83	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 2017, 19, 119.	5.0	43
84	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	1.8	14
85	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
86	Abstract 5290: Racial variation in terminal duct lobular unit (TDLU) involution in Chinese and Polish breast cancer patients. , 2017, , .		0
87	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31
88	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
89	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
90	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174

#	Article	IF	CITATIONS
91	Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium. Breast Cancer Research, 2016, 18, 98.	5.0	39
92	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
93	Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. JAMA Oncology, 2016, 2, 1295.	7.1	285
94	Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy. Hormones and Cancer, 2016, 7, 305-315.	4.9	13
95	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	5.0	43
96	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
97	Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics, 2016, 48, 563-568.	21.4	134
98	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.9	100
99	Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case–control study. Breast Cancer Research and Treatment, 2016, 159, 163-172.	2.5	48
100	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
101	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
102	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	3.3	2
103	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nature Genetics, 2016, 48, 1330-1338.	21.4	161
104	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
105	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	12.8	86
106	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
107	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
108	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19

#	Article	IF	CITATIONS
109	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	5.0	56
110	Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project. Cancer Causes and Control, 2016, 27, 1429-1435.	1.8	18
111	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
112	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Research, 2016, 18, 24.	5.0	18
113	Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue. Breast Cancer Research and Treatment, 2016, 158, 341-350.	2.5	5
114	Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities. Cancer Prevention Research, 2016, 9, 149-158.	1.5	42
115	Highâ€throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	3.0	19
116	Response. Journal of the National Cancer Institute, 2016, 108, djv441.	6.3	0
117	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38
118	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
119	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
120	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. British Journal of Cancer, 2016, 114, 298-304.	6.4	7
121	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
122	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
123	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
124	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genetics, 2016, 12, e1006493.	3.5	98
125	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
126	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes and Cancer, 2016, 7, 229-239.	1.9	12

#	Article	IF	CITATIONS
127	Abstract 4283: Relationship between mammographic breast density and measures of terminal duct lobular unit involution among women diagnosed with estrogen receptor positive breast cancer. , 2016, , .		0
128	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
129	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
130	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.4	0
131	SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	1.8	20
132	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
133	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
134	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2015, 1, 18-32.	3.0	24
135	Plasma Autoantibodies Associated with Basal-like Breast Cancers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1332-1340.	2.5	42
136	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine, 2015, 2, 681-689.	6.1	56
137	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
138	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
139	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
140	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
141	Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. British Journal of Cancer, 2015, 112, 61-68.	6.4	27
142	A robust association test for detecting genetic variants with heterogeneous effects. Biostatistics, 2015, 16, 5-16.	1.5	1
143	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
144	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56

#	Article	IF	CITATIONS
145	Tumor Intrinsic Subtype Is Reflected in Cancer-Adjacent Tissue. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 406-414.	2.5	72
146	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 2015, 17, 18.	5.0	20
147	Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. Breast Cancer Research and Treatment, 2015, 150, 457-466.	2.5	7
148	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. American Journal of Human Genetics, 2015, 97, 576-592.	6.2	1,098
149	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	21.4	357
150	Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. Journal of the National Cancer Institute, 2015, 107, djv223.	6.3	34
151	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	5.5	51
152	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
153	Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Human Molecular Genetics, 2015, 24, 1177-1184.	2.9	38
154	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
155	Abstract 4682: Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease. , 2015, , .		2
156	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15
157	Abstract 5570: Heterogeneity of luminal breast cancer characterized by immunohistochemical expression of basal markers. , 2015, , .		0
158	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
159	Terminal Duct Lobular Unit Involution of the Normal Breast: Implications for Breast Cancer Etiology. Journal of the National Cancer Institute, 2014, 106, .	6.3	67
160	Circulating Sex Hormones and Terminal Duct Lobular Unit Involution of the Normal Breast. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2765-2773.	2.5	23
161	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
162	Additive Interactions Between Susceptibility Single-Nucleotide Polymorphisms Identified in Genome-Wide Association Studies and Breast Cancer Risk Factors in the Breast and Prostate Cancer Cohort Consortium. American Journal of Epidemiology, 2014, 180, 1018-1027.	3.4	36

#	Article	IF	CITATIONS
163	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
164	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
165	Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. Breast Cancer Research, 2014, 16, R74.	5.0	34
166	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
167	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Human Molecular Genetics, 2014, 23, 2490-2497.	2.9	56
168	Reproductive windows, genetic loci, and breast cancer risk. Annals of Epidemiology, 2014, 24, 376-382.	1.9	7
169	Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Research and Treatment, 2014, 143, 181-187.	2.5	16
170	Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis, 2014, 35, 1737-1744.	2.8	50
171	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
172	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	2.9	137
173	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Geneâ€Environment Interactions. Genetic Epidemiology, 2014, 38, 84-93.	1.3	28
174	Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case–Control Study from Poland. Hormones and Cancer, 2014, 5, 42-50.	4.9	29
175	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.9	24
176	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nature Communications, 2014, 5, 5303.	12.8	109
177	Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 934-945.	2.5	37
178	Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. Cancer Causes and Control, 2014, 25, 1587-1593.	1.8	37
179	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	6.4	21
180	ERÎ ² splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Research and Treatment, 2014, 146, 657-667.	2.5	39

#	Article	IF	CITATIONS
181	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
182	Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Research and Treatment, 2014, 144, 467-478.	2.5	149
183	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
184	Benign Breast Tissue Composition in Breast Cancer Patients: Association with Risk Factors, Clinical Variables, and Gene Expression. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2810-2818.	2.5	21
185	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
186	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	2
187	Abstract 944: Translational implications of the 19q12 bladder cancer GWAS signal for aggressive bladder cancer. , 2014, , .		0
188	Abstract 385: Tamoxifen-resistant breast cancer: DNA methylation and expression of MAGED1. , 2014, , .		1
189	Abstract 874: Autoantibody biomarker discovery in basal-like breast cancer using nucleic acid programmable protein array. , 2014, , .		0
190	Abstract C11: Impact of pathologic specimen quality on classifying molecular subtypes of breast cancer: A pilot study from three hospitals in Ghana, Africa. , 2014, , .		0
191	Nonsteroidal antiâ€inflammatory drugs and other analgesic use and bladder cancer in northern New England. International Journal of Cancer, 2013, 132, 162-173.	5.1	20
192	Emerging Concepts in Breast Cancer Risk Prediction. Current Obstetrics and Gynecology Reports, 2013, 2, 43-52.	0.8	8
193	A versatile protein microarray platform enabling antibody profiling against denatured proteins. Proteomics - Clinical Applications, 2013, 7, 378-383.	1.6	34
194	Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer. Cancer Research, 2013, 73, 2211-2220.	0.9	107
195	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
196	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
197	The associations between a polygenic score, reproductive and menstrual risk factors and breast cancer risk. Breast Cancer Research and Treatment, 2013, 140, 427-434.	2.5	15
198	Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. Breast Cancer Research and Treatment, 2013, 137, 837-847.	2.5	21

#	Article	IF	CITATIONS
199	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
200	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. International Journal of Cancer, 2013, 132, 2044-2055.	5.1	11
201	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
202	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
203	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome–wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	3.1	26
204	Plasma Carotenoid- and Retinol-Weighted Multi-SNP Scores and Risk of Breast Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 927-936.	2.5	15
205	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	3.5	136
206	Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size. Journal of Medical Genetics, 2013, 50, 666-673.	3.2	12
207	Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer. Clinical Cancer Research, 2013, 19, 4972-4982.	7.0	51
208	Quantitative analysis of TDLUs using adaptive morphological shape techniques. Proceedings of SPIE, 2013, 8676, .	0.8	14
209	Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, <i>SLC14A1</i> . International Journal of Cancer, 2013, 133, 3008-3013.	5.1	24
210	Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Menopause, 2013, 20, 354-358.	2.0	12
211	Abstract 3651: Parity-related molecular signatures and breast cancer heterogeneity , 2013, , .		0
212	Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Human Molecular Genetics, 2012, 21, 1918-1930.	2.9	71
213	The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: A Unique Resource for Defining the "Molecular Histology―of the Breast. Cancer Prevention Research, 2012, 5, 528-535.	1.5	47
214	Unraveling Genes, Hormones, and Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 641-642.	6.3	3
215	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
216	Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. Journal of Medical Genetics, 2012, 49, 601-608.	3.2	58

#	Article	IF	CITATIONS
217	Common genetic variants in the <i>PSCA</i> gene influence gene expression and bladder cancer risk. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4974-4979.	7.1	79
218	<i>CHEK2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	1.6	162
219	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	2.9	80
220	Likelihood Ratio Test for Detecting Gene (G)-Environment (E) Interactions Under an Additive Risk Model Exploiting G-E Independence for Case-Control Data. American Journal of Epidemiology, 2012, 176, 1060-1067.	3.4	37
221	Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research, 2012, 18, 118-126.	7.0	54
222	Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers. Breast Cancer Research, 2012, 14, R64.	5.0	39
223	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
224	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
225	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
226	Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Research and Treatment, 2012, 131, 287-294.	2.5	32
227	Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics, 2012, 131, 479-490.	3.8	5
228	Large-Scale Pathway-Based Analysis of Bladder Cancer Genome-Wide Association Data from Five Studies of European Background. PLoS ONE, 2012, 7, e29396.	2.5	36
229	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	2.5	51
230	Abstract LB-336: Association of variant rs2046210 at 6q25.1 (ESR1) with breast cancer risk suggests heterogeneity by E-cadherin tumor tissue expression. , 2012, , .		0
231	Abstract LB-337: Synergistic effects of twelve common genetic polymorphisms and smoking habits on absolute risk of bladder cancer. , 2012, , .		0
232	Abstract 4465: Breast cancer risk factor associations with breast tissue morphometry: results from the Komen for the Cure® Tissue Bank. , 2012, , .		0
233	Abstract 1658: Post-GWAS genetic and functional studies for bladder cancer: An uncommon protective synonymous coding variant within the UGT1A6 gene explains the GWAS signal and affects cellular detoxification. , 2012, , .		0
234	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27

#	Article	IF	CITATIONS
235	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
236	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
237	An unusual suspect: an uncommon human-specific synonymous coding variant within the UGT1A6 gene explains a GWAS signal and protects against bladder cancer. Genome Biology, 2011, 12, .	8.8	0
238	A novel functional variant in 8q24 is associated with regulation of prostate stem cell antigen (PSCA) gene expression and bladder cancer risk. Genome Biology, 2011, 12, .	8.8	0
239	Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. Breast Cancer Research, 2011, 13, R42.	5.0	18
240	A role for XRCC2 gene polymorphisms in breast cancer risk and survival. Journal of Medical Genetics, 2011, 48, 477-484.	3.2	47
241	CSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis, 2011, 32, 182-189.	2.8	110
242	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
243	TGF-β Signaling Pathway and Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1112-1119.	2.5	49
244	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Human Molecular Genetics, 2011, 20, 4282-4289.	2.9	100
245	A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenetics and Genomics, 2011, 21, 231-236.	1.5	60
246	Abstract 2783: A novel functional variant is associated with regulation of the prostate stem cell antigen (PSCA) gene and bladder cancer risk in males. , 2011, , .		0
247	Effect modification of endocrine disruptors and testicular germ cell tumour risk by hormoneâ€metabolizing genes. Journal of Developmental and Physical Disabilities, 2010, 33, 588-596.	3.6	31
248	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research, 2010, 12, R110.	5.0	82
249	Expression of TGF- $\hat{1}^2$ signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Research and Treatment, 2010, 121, 727-735.	2.5	51
250	Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case–control study from Poland. British Journal of Cancer, 2010, 103, 1097-1102.	6.4	29
251	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	21.4	493
252	Pathway Analysis of Breast Cancer Genome-Wide Association Study Highlights Three Pathways and One Canonical Signaling Cascade. Cancer Research, 2010, 70, 4453-4459.	0.9	112

#	Article	IF	CITATIONS
253	Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 992-999.	2.5	54
254	Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis, 2010, 31, 827-833.	2.8	42
255	Polymorphisms in <i>GSTT1</i> , <i>GSTZ1</i> , and <i>CYP2E1</i> , Disinfection By-products, and Risk of Bladder Cancer in Spain. Environmental Health Perspectives, 2010, 118, 1545-1550.	6.0	194
256	Abstract 2201: Pathway analysis of breast cancer genome wide association study highlights three pathways and one canonical signaling cascade. , 2010, , .		0
257	Abstract 2779: Relationship of mammographic density with breast cancer subtypes. , 2010, , .		Ο
258	DNA Hypermethylation of <i>ESR1</i> and <i>PGR</i> in Breast Cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3036-3043.	2.5	60
259	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. Cancer Research, 2009, 69, 6857-6864.	0.9	107
260	Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes and Control, 2009, 20, 361-368.	1.8	35
261	Genetic variation in hormone metabolizing genes and risk of testicular germ cell tumors. Cancer Causes and Control, 2008, 19, 917-929.	1.8	31
262	<i>TNF</i> polymorphisms and prostate cancer risk. Prostate, 2008, 68, 400-407.	2.3	42
263	Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 2008, 29, 1955-1962.	2.8	88
264	Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival. PLoS ONE, 2008, 3, e1651.	2.5	563
265	Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis, 2007, 29, 568-572.	2.8	29
266	Large-Scale Evaluation of Candidate Genes Identifies Associations between VEGF Polymorphisms and Bladder Cancer Risk. PLoS Genetics, 2007, 3, e29.	3.5	119
267	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis, 2007, 28, 1788-1793.	2.8	87
268	Genetic variation in the base excision repair pathway and bladder cancer risk. Human Genetics, 2007, 121, 233-242.	3.8	113
269	Large-scale evaluation of candidate genes for cancer identifies common genetic variants in vascular endothelial growth factor associated with bladder cancer risk. PLoS Genetics, 2005, preprint, e29.	3.5	1
270	Tracking Excess Deaths (TRACKED) – an interactive online tool to monitor excess deaths associated with the COVID-19 pandemic in the United Kingdom. Wellcome Open Research, 0, 5, 168.	1.8	2

#	Article	IF	CITATIONS
271	Longer-Term (≥2 Years) Survival in Patients with Glioblastoma in Population-Based Studies Pre- and Post-2005. SSRN Electronic Journal, 0, , .	0.4	0
272	Reproductive Factors and Risk of Breast Cancer by Tumour Subtypes Among Ghanaian Women: A Population-Based Case-Control Study. SSRN Electronic Journal, 0, , .	0.4	0
273	Tracking Excess Deaths (TRACKED) – an interactive online tool to monitor excess deaths associated with the COVID-19 pandemic in the United Kingdom. Wellcome Open Research, 0, 5, 168.	1.8	0
274	Analysis of cancer diagnoses from 2015-2019 within Machakos County, Kenya, support establishment of Cancer Centre in 2019 likely changing referral patterns. Wellcome Open Research, 0, 5, 290.	1.8	4
275	The oral microbiome and breast cancer and nonâ€malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study. International Journal of Cancer, 0, , .	5.1	13
276	Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. Breast Cancer Research and Treatment, 0, , .	2.5	3